Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies

Antimalarial chemotherapy relies on combination therapies (ACTs) consisting of an artemisinin derivative and a partner drug. Here, the authors study the effects of globally prevalent mutations in a multidrug resistance transporter (PfMDR1) on the parasite’s susceptibility to ACT drugs.

Dades bibliogràfiques

Autors principals:	M. Isabel Veiga, Satish K. Dhingra, Philipp P. Henrich, Judith Straimer, Nina Gnädig, Anne-Catrin Uhlemann, Rowena E. Martin, Adele M. Lehane, David A. Fidock
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2016-05-01
Col·lecció:	Nature Communications
Accés en línia:	https://doi.org/10.1038/ncomms11553
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!